Secretary of Commerce-designate Howard Lutnick told a Senate committee that the threat of imposing a 25% tariff was to get Canada and Mexico to “respect” the United States and stop the flow of ...

Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...

Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target Maximize Your Portfolio ...

CVS Health (CVS) stock was upgraded by Cantor Fitzgerald to Overweight after the company posted strong Q4 results earlier in ...

Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating ... Brayer noted that while the full impact of Alyftrek on the company's financials is yet to be determined, a swift transition of ...

In their analysis, Cantor Fitzgerald focused on SanDisk's provision of a target financial model that spans business cycles, as well as its forecasts for the March quarter. The guidance included ...

Cantor Fitzgerald raised concerns about the Magnificent Seven stocks, suggesting they may be at risk of losing investor interest as fund flows shift to other sectors. Revenue projections for 2025 are ...

Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on Vertex ... Brayer noted that while the full impact of Alyftrek on the company's financials is yet to be determined, a swift transition of ...

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC has several regulatory decisions this year ...